European Journal of Dermatology

, Volume 25, Issue 6, pp 586–594 | Cite as

Defining and recognising locally advanced basal cell carcinoma

  • Jean Michel Amici
  • Maxime Battistella
  • Marie Beylot-Barry
  • Anne Chatellier
  • Sophie Dalac-Ra
  • Brigitte Dreno
  • Claire Falandry
  • Nicolas Froget
  • Damien Giacchero
  • Jean Jacques Grob
  • Pierre Guerreschir
  • Marie-Thérèse Leccia
  • Olivier Malard
  • Laurent Mortier
  • Emilie Routier
  • Andreea Stefan
  • Dinu Stefan
  • Pierre-Emmanuel Stoebner
  • Nicole Basset-Seguin
Review
  • 31 Downloads

Abstract

Background

Rarely, basal cell carcinomas (BCCs) have the potential to become extensively invasive and destructive, a phenomenon that has led to the term “locally advanced BCC” (laBCC). We identified and described the diverse settings that could be considered “locally advanced”.

Methods

The panel of experts included oncodermatologists, dermatological and maxillofacial surgeons, pathologists, radiotherapists and geriatricians. During a 1-day workshop session, an interactive flow/sequence of questions and inputs was debated.

Results

Discussion of nine cases permitted us to approach consensus concerning what constitutes laBCC. The expert panel retained three major components for the complete assessment of laBCC cases: factors of complexity related to the tumour itself, factors related to the operability and the technical procedure, and factors related to the patient. Competing risks of death should be precisely identified. To ensure homogeneous multidisciplinary team (MDT) decisions in different clinical settings, the panel aimed to develop a practical tool based on the three components.

Conclusions

The grid presented is not a definitive tool, but rather, it is a method for analysing the complexity of laBCC.

Keywords

basal cell carcinoma definition locally advanced 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Rubin AI, Chen EH, Ratner D. Basal-cell carcinoma. N Engl J Med 2005; 353: 2262–9.CrossRefPubMedGoogle Scholar
  2. 2.
    Dandurand M, Petit T, Martel P, Guillot B. Management of basal cell carcinoma in adults: Clinical practice guidelines. Eur J Dermatol 2006; 16: 394–401.PubMedGoogle Scholar
  3. 3.
    Trakatelli M, Morton C, Nagore E, et al. Update of the European guidelines for basal cell carcinoma management. Eur J Dermatol 2014; 24: 312–29.PubMedGoogle Scholar
  4. 4.
    Maly TJ, Sligh JE. Defining locally advanced basal cell carcinoma. J Drugs Dermatol 2014; 13: 528–9.PubMedGoogle Scholar
  5. 5.
    Sakura CY, Calamel PM. Comparison of treatment modalities for recurrent basal cell carcinoma. Plast Reconstr Surg 1979; 63: 492–6.CrossRefPubMedGoogle Scholar
  6. 6.
    Goldberg H, Tsalik M, Bernstein Z, Haim N. Cisplatin-based chemotherapy for advanced basal and squamous cell carcinomas. Harefuah 1994; 127, 217–21 & 286.PubMedGoogle Scholar
  7. 7.
    Lear JT, Corner C, Dziewulski P, et al. Challenges and new horizons in the management of advanced basal cell carcinoma: a UK perspective. Br J Cancer 2014; 111: 1476–81.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Peris K, Licitra L, Ascierto PA, et al. Identifying ocally advanced basal cell carcinoma eligible for treatment with vismodegib: an expert panel consensus. Future Oncology 2015; 11: 703–12.CrossRefPubMedGoogle Scholar
  9. 9.
    Dreier J, Cheng PF, Bogdan Alleman I, et al. Basal cell carcinoma in a tertiary referral centre–A systematic analysis. Br J Dermatol 2014; 171: 1066–72.CrossRefPubMedGoogle Scholar
  10. 10.
    Institut national du cancer. Summary Plan Plan 2014-2019. Accessed March 2, 2015 at http://www.e-cancer.fr/publications/93-plan-cancer/777-summary-plan-cancer-2014-2019-.Google Scholar
  11. 11.
    Jee BA, Lim H, Kwon SM, et al. Molecular classification of basal cell carcinoma of skin by gene expression profiling. Molecular Carcinogenesis 2015; 54: 1605–12.CrossRefPubMedGoogle Scholar
  12. 12.
    Hamid O, Goldenberg G. Identifying patients at risk for recurrent or advanced BCC. J Drugs Dermatol 2013; 12: 1246–52.PubMedGoogle Scholar
  13. 13.
    Renaud-Vilmer C, Basset-Seguin N. Carcinomes basocellulaires. Rev Praticien 2014; 64: 37–44.Google Scholar
  14. 14.
    Popadic M. Dermoscopic features in different morphologic types of basal cell carcinoma. Dermatol Surg 2014; 40: 725–32.PubMedGoogle Scholar
  15. 15.
    Cho M, Gordon L, Rembielaks A, Woo TCS. Utility of radiotherapy for treatment of basal cell carcinoma: review. Br J Dermatol 2014; 171: 968–73.CrossRefPubMedGoogle Scholar
  16. 16.
    Durbec M, Couloigner V, Tronche S, et al. Guidelines of the French Society of Otorhinolaryngology (SFORL), short version. Extension assessment and principles of resection in cutaneous head and neck tumours. Eur Ann Otorhinolaryngol Head Neck Dis 2014; 131: 375–83.CrossRefPubMedGoogle Scholar
  17. 17.
    Haute Autorité de Santé. Transparency committee. Opinion 18 December 2013, Erivedge 150 mg, gélule. Accessed March 2, 2015 at http://www.has-sante.fr/portail/jcms/c_1721873/fr/erivedgevismodegib-antineoplasique?xtmc=&xtcr=1.Google Scholar
  18. 18.
    Sekulic A, Migden MR, Oro AE, et al. Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med 2012; 366: 2171–9.CrossRefPubMedGoogle Scholar
  19. 19.
    Dréno B, Kuntsfeld R, Grob JJ, et al. Vismodegib, a hedgehog pathway inhibitor, in advanced basal cell carcinoma: an interim analysis of the STEVIE study in 500 patients. Presented at the Society for Melanoma Research 2014; November 13-16, 2014; Zurich, Switzerland.Google Scholar
  20. 20.
    Balducci L. Management of cancer in the elderly. Oncology (Williston Park) 2006; 20: 135–43, discussion 144, 146, 151-2.Google Scholar
  21. 21.
    Rubenstein LZ, Stuck AE, Siu AL, Wieland D. Impacts of geriatric evaluation and management programs on defined outcomes: overview of the evidence. J Am Geriatr Soc 1991; 39: 8S-16S, discussion 17S-18S.CrossRefGoogle Scholar
  22. 22.
    Yourman LC, Lee SJ, Schonberg MA, Widera EW, Smith AK. Prognostic indices for older adults. A systematic review. JAMA 2012; 307: 182–92.PubMedGoogle Scholar
  23. 23.
    Lee SJ, Lindquist K, Segal MR, Covinsky KE. Development and validation of a prognostic index for 4-year mortality in older adults. JAMA 2006; 295: 801–8.CrossRefPubMedGoogle Scholar
  24. 24.
    Mortier L, Saiag Ph, Leccia MT, et al. A phase II study to assess vismodegib in the neoadjuvant treament of locally advanced basal cell carcinoma (LaBCC): the vismodegib neoadjuvant (VISMONEO) study. abstract ASCO 2014 # 307A.Google Scholar
  25. 25.
    Rowe G, Wright G, Bolger F. Delphi: a reevaluation of research and theory. Technol Forecast Soc Change 1991; 39: 235–325.CrossRefGoogle Scholar

Copyright information

© John Libbey Eurotext 2015

Authors and Affiliations

  • Jean Michel Amici
    • 1
    • 3
  • Maxime Battistella
    • 1
    • 4
  • Marie Beylot-Barry
    • 1
    • 3
  • Anne Chatellier
    • 1
    • 5
  • Sophie Dalac-Ra
    • 1
    • 6
  • Brigitte Dreno
    • 1
    • 7
  • Claire Falandry
    • 1
    • 8
  • Nicolas Froget
    • 1
    • 8
  • Damien Giacchero
    • 1
    • 9
  • Jean Jacques Grob
    • 1
    • 10
  • Pierre Guerreschir
    • 1
    • 11
  • Marie-Thérèse Leccia
    • 1
    • 12
  • Olivier Malard
    • 1
    • 7
  • Laurent Mortier
    • 1
    • 14
  • Emilie Routier
    • 1
    • 13
  • Andreea Stefan
    • 1
    • 5
  • Dinu Stefan
    • 1
    • 5
  • Pierre-Emmanuel Stoebner
    • 1
    • 11
  • Nicole Basset-Seguin
    • 1
    • 2
    • 4
  1. 1.Basal cell carcinoma French Expert GroupParisFrance
  2. 2.hôpital Saint-LouisUniversité Paris 7ParisFrance
  3. 3.BordeauxFrance
  4. 4.ParisFrance
  5. 5.CaenFrance
  6. 6.DijonFrance
  7. 7.NantesFrance
  8. 8.LyonFrance
  9. 9.NiceFrance
  10. 10.MarseilleFrance
  11. 11.LilleFrance
  12. 12.GrenobleFrance
  13. 13.VillejuifFrance
  14. 14.NîmesFrance

Personalised recommendations